You are here

Press Releases

March 28, 2017
WASHINGTON, D.C. – Andrew Fish, executive director of AdvaMedDx, and chief strategy officer of AdvaMed, today issued the following statement regarding release of a discussion draft of the Diagnostic Accuracy and Innovation Act (DAIA) in the U.S.... Read More
January 20, 2017
New Framework Provides Recommendations for Optimizing Diagnostic Solutions to Combat AMR Davos-Klosters, Switzerland – AdvaMedDx, the association representing manufacturers of diagnostic tests to promote wellness, improve patient outcomes, and... Read More
November 21, 2016
WASHINGTON, D.C. – Andrew Fish, executive director of AdvaMedDx, today issued the following statement regarding FDA’s decision not to release at this time a final guidance on oversight of laboratory developed tests: “AdvaMedDx is disappointed that... Read More
October 17, 2016
WASHINGTON, DC – Scott Whitaker, president and CEO of the Advanced Medical Technology Association (AdvaMed), and Andy Fish, executive director of AdvaMedDx, today jointly issued the following statement on the Final Report of the Cancer Moonshot Task... Read More
September 20, 2016
WASHINGTON, D.C. – Andrew Fish, executive director of AdvaMedDx, issued the following statement on today’s Senate HELP Committee hearing on laboratory testing in the era of precision medicine: “AdvaMedDx commends the Senate HELP Committee for... Read More
August 22, 2016
Hercules, CA – (August 22, 2016) – Today, U.S. Representative Mike Thompson (CA-5) joined members of the California health care community to discuss how innovative diagnostic tests are a key contributor to the U.S. health care system, empowering... Read More
June 29, 2016
WASHINGTON, DC – Scott Whitaker, president and CEO of the Advanced Medical Technology Association (AdvaMed) and Andy Fish, executive director of AdvaMedDx, today jointly issued the following statement in support of Vice President Biden’s National... Read More
June 17, 2016
Wanda Moebius, spokesperson for AdvaMedDx, issued the following statement on CMS’s final rule implementing the new Clinical Diagnostic Lab Test Payment System that was established under the Protecting Access to Medicare Act (PAMA) of 2014: “... Read More
November 17, 2015
Andrew Fish, executive director of AdvaMedDx, issued the following statement on today’s House Energy & Commerce Health Subcommittee hearing on the regulation of diagnostic tests and laboratory operations: “Diagnostic tests are a cornerstone of... Read More
June 2, 2015
Andrew Fish, executive director of AdvaMedDx, issued the following statement on today’s White House Forum on Antibiotic Stewardship: “AdvaMedDx commends the administration for convening today’s meeting of key stakeholders dedicated to reducing... Read More

Pages